Our vision is to offer affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence in the case of existing and newly emerging infectious disease outbreaks.
- Emergex Vaccines awarded SBRI contract by Innovate UK 5 April 2017
- Emergex Vaccines approved as member of the Social Stock Exchange 20 February 2017
- Emergex Vaccines provides an update on Agreement with Midatech Pharma 22 November 2016